TY - JOUR
T1 - Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena
T2 - An Official American Thoracic Society Report
AU - Vukmirovic, Milica
AU - Benam, Kambez H.
AU - Rose, Jason J.
AU - Turner, Scott
AU - Magin, Chelsea M.
AU - Lagares, David
AU - Cohen, Alan H.
AU - Kaminski, Naftali
AU - Hirota, Jeremy A.
AU - Maher, Toby M.
AU - Konigshoff, Melanie
AU - Mallampalli, Rama K.
AU - Sheppard, Dean
AU - Tarran, Robert
AU - Gomer, Richard H.
AU - Kenyon, Nicholas J.
AU - Morris, David
AU - Hobbie, Silke
AU - Raju, S. Vamsee
AU - Petrache, Irina
AU - Watkins, Timothy
AU - Kumar, Rishav
AU - Lam, Wilbur A.
AU - Sherer, Todd
AU - Hecker, Louise
PY - 2024/1/1
Y1 - 2024/1/1
N2 - "Translational medicine" has been a buzzword for over two decades. The concept was intended to be lofty, to reflect a new "bench-to-bedside" approach to basic and clinical research that would bridge fields, close gaps, accelerate innovation, and shorten the time and effort it takes to bring novel technologies from basic discovery to clinical application. Has this approach been successful and lived up to its promise? Despite incredible scientific advances and innovations developed within academia, successful clinical translation into real-world solutions has been difficult. This has been particularly challenging within the pulmonary field, because there have been fewer U.S. Food and Drug Administration-approved drugs and higher failure rates for pulmonary therapies than with other common disease areas. The American Thoracic Society convened a working group with the goal of identifying major challenges related to the commercialization of technologies within the pulmonary space and opportunities to enhance this process. A survey was developed and administered to 164 participants within the pulmonary arena. This report provides a summary of these survey results. Importantly, this report identifies a number of poorly recognized challenges that exist in pulmonary academic settings, which likely contribute to diminished efficiency of commercialization efforts, ultimately hindering the rate of successful clinical translation. Because many innovations are initially developed in academic settings, this is a global public health issue that impacts the entire American Thoracic Society community. This report also summarizes key resources and opportunities and provides recommendations to enhance successful commercialization of pulmonary technologies.
AB - "Translational medicine" has been a buzzword for over two decades. The concept was intended to be lofty, to reflect a new "bench-to-bedside" approach to basic and clinical research that would bridge fields, close gaps, accelerate innovation, and shorten the time and effort it takes to bring novel technologies from basic discovery to clinical application. Has this approach been successful and lived up to its promise? Despite incredible scientific advances and innovations developed within academia, successful clinical translation into real-world solutions has been difficult. This has been particularly challenging within the pulmonary field, because there have been fewer U.S. Food and Drug Administration-approved drugs and higher failure rates for pulmonary therapies than with other common disease areas. The American Thoracic Society convened a working group with the goal of identifying major challenges related to the commercialization of technologies within the pulmonary space and opportunities to enhance this process. A survey was developed and administered to 164 participants within the pulmonary arena. This report provides a summary of these survey results. Importantly, this report identifies a number of poorly recognized challenges that exist in pulmonary academic settings, which likely contribute to diminished efficiency of commercialization efforts, ultimately hindering the rate of successful clinical translation. Because many innovations are initially developed in academic settings, this is a global public health issue that impacts the entire American Thoracic Society community. This report also summarizes key resources and opportunities and provides recommendations to enhance successful commercialization of pulmonary technologies.
KW - academic entrepreneurship
KW - commercialization
KW - intellectual property
KW - pulmonary
KW - technology development
UR - http://www.scopus.com/inward/record.url?scp=85181396057&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.202310-872ST
DO - 10.1513/AnnalsATS.202310-872ST
M3 - Article
C2 - 37903340
AN - SCOPUS:85181396057
SN - 2325-6621
VL - 21
SP - 1
EP - 11
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 1
ER -